The Evolving Needs of Therapeutic mRNA Developers Insights on the next wave of challenges mRNA innovators face as an increasing number of therapeutics move through the pipeline. Read Article Behind the Headlines Panel Discussion Christian Cobaugh, Ph.D., Vernal Biosciences founder…
How Vernal Helped Akagera Boost Vaccine Efficacy, Cut Costs, and Speed Development Pioneering mRNA Therapies for Infectious Diseases in Cost-Sensitive Regions Founded in 2019, Akagera Medicines is advancing novel liposomal formulations of antibacterial drugs to enhance drug delivery and uptake…
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a…
In the fast-paced world of biopharmaceuticals, choosing the right contract development and manufacturing organization (CDMO) is crucial to the success of your drug development program. At Vernal Biosciences, we pride ourselves on being a US-based CDMO that produces all products domestically. Here…
If you are not on our mailing list, email us at [email protected]! You can click “contact us” in the upper right hand corner of this webpage to inquire about our Cas9 Demo batch, and HERE to watch the video of…
Experience the incredible insights Vernal has to offer regarding its cutting-edge capping technology and the exceptional quality of our mRNA. We will be showcasing this groundbreaking information through three posters at the International mRNA Health Conference in Berlin. You can…
CRISPR-Cas9 RNA-DNA complex. Structure of Cas9 endonuclease (yellow-orange) complexed with a guide RNA (blue), a target DNA (pink) and a non-target DNA (green). The revolutionary CRISPR-Cas gene editing technology has unlocked unprecedented possibilities in genome engineering, gene therapy, and cell…
Vernal is excited to announce its new partnership with REPROCELL, furthering our mission to democratize access to mRNA, a life-changing technology, around the world. REPROCELL is a trusted leader in iPSC reprograming technologies and GMP iPSC manufacturing based in Japan. Together with REPROCELL, we…
Find our latest article on Businesswire here: Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing Click the orange “Contact Us” button in the top right hand corner to find out more!
Every success has an origin story. Check out this new VT Digger article on how CEO Christian Cobaugh, Ph.D. founded Vernal Biosciences, and what makes Vernal uniquely situated to meet mRNA process development and manufacturing needs.
Vernal has successfully demonstrated its ability to manufacture high quality mRNA using CGMP-compliant platform. We now offer the first integrated platform for CGMP production of MCB, pDNA, mRNA, and LNP at our GMP facility. Contact us today to reserve your GMP…
After a successful extension of its Series A funding, Vernal Biosciences was featured in an Endpoints News article by Tyler Patchen. Find out how we are using these funds to widen our offerings and support the mRNA community, then click…